View
222
Download
6
Tags:
Embed Size (px)
Citation preview
Psych 181: Dr. AnagnostarasLec 10: Marijuana
Marijuana and cannabinoidscannabinoidsMarijuana and cannabinoidscannabinoids
Cannabis sativaCannabis sativa, hemp, hempOne of earliest non-food plants cultivatedOne of earliest non-food plants cultivated fiber for rope, seeds for oil and birdseedfiber for rope, seeds for oil and birdseed
8000 BC 2700 BC 2000 BC 1000 AD 1850s 1996
1st archaeological evidenceof hemp use
Medical usein China
Ritual usein India
Hashish use inArab world
Westerm world find bioactiv.
Use semi-legal in CA/AZ
from Childers & Breivogel (1998)
Marijuana and cannabinoidscannabinoidsMarijuana and cannabinoidscannabinoids
CannabinoidsCannabinoids pharmacologically active compoundspharmacologically active compounds over 60 (delta-9-tetrahydrocannabinol (over 60 (delta-9-tetrahydrocannabinol (9-9-
THC), THC), 8-THC, cannabinol, etc.)8-THC, cannabinol, etc.)
O CH2CH2
9-Tetrahydrocannabinol
OH
CH3
H3C
H3C CH2 CH3CH2
Forms and preparationsForms and preparations
MarijuanaMarijuana mixture of leaves, stems, topsmixture of leaves, stems, tops 1960’s: 1-3% THC; 1990’s: up to 8-10%1960’s: 1-3% THC; 1990’s: up to 8-10%
“Bubble Gum” “Big Bud” “Dutch Northern Lights”
Forms and preparationsForms and preparations
HashishHashish dried resin from top of female plantdried resin from top of female plant THC usually 2-5%, but up to 15%THC usually 2-5%, but up to 15%
Hash OilHash Oil organic extractionorganic extraction
from hashishfrom hashish THC usually ~ 10-20%THC usually ~ 10-20%
up to 70%up to 70%
Synthetic cannabinoidsSynthetic cannabinoids
Developed for researchDeveloped for research Some very potentSome very potent
CH2
CH3N
WIN 55212
O
C O
N
O
HistoryHistory
Second only toSecond only toalcohol & tobaccoalcohol & tobacco
HistoryHistory
1960
PharmacokineticsPharmacokinetics
AbsorptionAbsorption very lipid solublevery lipid soluble good absorption if smoked (20-37%)good absorption if smoked (20-37%) rapid peakrapid peak
100
1
100
1
0 1 2 3 4 0 1 2 3 4
Time (hr)
Injection Smoking
Blo
od
leve
ls
17.2
THC Administration
PharmacokineticsPharmacokinetics
AbsorptionAbsorption slow absorption with oralslow absorption with oral
Blo
od
leve
ls
100
1
Time (hr)0 1 2 3 4 5 6
Oral
17.2
THC Administration
0 120 240 360Time (min)
Intravenous (5 mg) Smoking (19 mg) Oral (20 mg)
Ra
ted
“h
igh
”
17.4
Metabolism and clearanceMetabolism and clearance
rapid initial drop due to redistribution to fatsrapid initial drop due to redistribution to fats slower metabolism in liverslower metabolism in liver metabolites may persist for a weekmetabolites may persist for a week
1. Primary metabolic product of 9-THC 9-THC (11-OH- (11-OH-9-THC) is more potent than 9-THC) is more potent than 9-THC 9-THC 2. 2. Delay between peak plasma levels and “high”Delay between peak plasma levels and “high”
Major biolgically active compound may be metabolite
Effects on behaviorEffects on behavior
Low - moderate dosesLow - moderate doses disinhibition, relaxation, drowsinessdisinhibition, relaxation, drowsiness feeling of well being, exhileration, euphoriafeeling of well being, exhileration, euphoria sensory - perceptual changessensory - perceptual changes recent memory impairmentrecent memory impairment balance/stability impairedbalance/stability impaired decreased muscle strength, small tremordecreased muscle strength, small tremor poor on complex motor tasks (e.g., driving)poor on complex motor tasks (e.g., driving)
Effects on behaviorEffects on behavior
Psychomotor performancePsychomotor performance
1.0
0.6
0.2
2 6 122 6 12
Simpleresponse time
Response time (divided attention)
Time (hr)Per
form
ance
dec
rem
ent
(s)
17.5
Effects on behaviorEffects on behavior
High dosesHigh doses pseudohallucinationspseudohallucinations synesthesiassynesthesias impaired judgement, reaction timeimpaired judgement, reaction time pronounced motor impairmentpronounced motor impairment increasingly disorganized thoughts, increasingly disorganized thoughts,
confusion, paranoia, agitationconfusion, paranoia, agitation
Not lethal even at very high dosesNot lethal even at very high doses
Repeated administrationRepeated administration
Chronic THC Control
17.9
3H-CP-55,940 Binding
Tolerance
Repeated administrationRepeated administration
Long-term effects Amotivational syndrome?Amotivational syndrome?
Potential medical usesPotential medical uses
Glaucoma (increased intraocular pressure)Glaucoma (increased intraocular pressure) Antiemetic (reduce nausea and vomiting)Antiemetic (reduce nausea and vomiting) AnticonvulsantAnticonvulsant Enhance appetite (e.g., AIDS patients)Enhance appetite (e.g., AIDS patients) AnalgesicAnalgesic
THC versus marijuana controversy?THC versus marijuana controversy?
Mechanisms of actionMechanisms of action
Nonspecific?Nonspecific? e.g., membrane fluidity changese.g., membrane fluidity changes
Specific?Specific?is there a cannabinoid receptor?is there a cannabinoid receptor? small doses effectivesmall doses effective effects of d and l isomers differenteffects of d and l isomers different marked structure-function effectsmarked structure-function effects inhibits cAMP formation via G protein inhibits cAMP formation via G protein (1986)(1986)
Mechanisms of actionMechanisms of action
Is there a cannabinoid receptor?Is there a cannabinoid receptor?
Development of synthetic cannabinoidsDevelopment of synthetic cannabinoids 9-THC binds weakly and not full agonist9-THC binds weakly and not full agonist CP and WIN series of compounds andCP and WIN series of compounds and
antagonists (1986-1990s) antagonists (1986-1990s) first binding experiments (1988)first binding experiments (1988) first localization (1990)first localization (1990) CB-1 receptor cloned (1990)CB-1 receptor cloned (1990) CB-2 cloned (1993)CB-2 cloned (1993)
Cannabinoid receptorCannabinoid receptorCannabinoid receptorCannabinoid receptor
17.8[3H]CP-55,940 Binding
Cannabinoid receptorCannabinoid receptorCannabinoid receptorCannabinoid receptor
Receptor localizationReceptor localization conserved across mammalian speciesconserved across mammalian species similar to cAMP distributionsimilar to cAMP distribution
binding inhibitedbinding inhibitedby cAMP analoguesby cAMP analogues
both CB-1 and CB-2 both CB-1 and CB-2 (peripheral) receptors are(peripheral) receptors areG protein coupledG protein coupled
receptor density very high,receptor density very high,rivalling amino acid receptorsrivalling amino acid receptors
Endogenous cannabinoidsEndogenous cannabinoids
AnandamideAnandamide from Sanskrit for “bliss”from Sanskrit for “bliss” arachidonic acid derivative arachidonic acid derivative (1992)(1992)
similar actions to cannabinoidssimilar actions to cannabinoids inhibit cAMP via cannabinoid receptorinhibit cAMP via cannabinoid receptor inhibit binding of cannabinoidsinhibit binding of cannabinoids only partial agonist at CB-1only partial agonist at CB-1 decrease motor activitydecrease motor activity antinociceptive effectsantinociceptive effects
CONHCH2CH2OH
Anandamide (Anandamide 20:4,n-6)
Endogenous cannabinoidsEndogenous cannabinoids
OthersOthers
2-arachidonyl glycerol2-arachidonyl glycerol full agonist at CB-1 and in brain in higher full agonist at CB-1 and in brain in higher
conc. than anandamideconc. than anandamide
additional unidentified compounds have been additional unidentified compounds have been foundfound
CONHCH2CH2OH
Anandamide (Anandamide 20:4,n-6)
Locus of actionsLocus of actions
Relationship between action & sites of Relationship between action & sites of action not knownaction not known
Speculation:Speculation: memory effects - hippocampusmemory effects - hippocampus reward - mesostriatal DA systemreward - mesostriatal DA system motor activity - basal ganglia, cerebellummotor activity - basal ganglia, cerebellum analgesic effects - spinal cord and in analgesic effects - spinal cord and in
peripheral tissue peripheral tissue (endogenous compounds (endogenous compounds effective via non-opiate mechanism)effective via non-opiate mechanism)
Actions on DA systemsActions on DA systemsActions on DA systemsActions on DA systems
Injection
150
100
0 40Time (min)
80 120
1.0 mg/kg THC0.5 mg/kg THCVehicle
% c
han
ge
in a
ccu
mb
ens
DA